Nowotwory
Journal of Oncology

Radiotherapy and immunotherapy

Author: Ewa Sierko

How to cite:

Sierko E. Radiotherapy and immunotherapy.
NOWOTWORY J Oncol 2022; 72 (Ahead of print).

Radiotherapy and immunotherapy

Ewa Sierko[1, 2]

1. Radiotherapy Department 1, Bialystok Oncology Centre, Bialystok, Poland
2. Oncology Clinic, Medical University of Bialystok, Bialystok, Poland

Abstract

Radiation therapy is one of the standard treatment method in cancer patients. Apart from exerting the killing effect towards cancer cells it produces modulation effect on local and systemic disease. Recently, immunotherapy, aiming mainly to immune checkpoint blockade, has become widely used in many clinical situations. Experimental and clinical studies indicate that the combination of both radiation therapy and immunotherapy may be beneficial in cancer patient population in different clinical scenarios. Durvalumab maintenance therapy after radiochemotherapy in stage III NSCLC patients was introduced to the standard clinical care. The paper discusses shortly the pathogenesis of the mutual interaction between radiation therapy and immunotherapy as well available preclinical and clinical data concerning this promising treatment combination.

Key words: radiation therapy, radiotherapy, immunotherapy, checpoint inhibitors, cancer

Introduction

Radiation therapy (RT) plays an important role in cancer patients cure, prolongation of their life and alleviation of cancer-related symptoms. The death of cancer cells due to DNA damage (eg. apoptosis, autophagy) during cell division or in interphase (eg. lymphocytes) is the main mechanism of RT. Recent evidence revealed that efficacy of RT results from optimal immune response triggered in irradiated tissue. Experimental studies demonstrated that

mice lacking T and B cells required higher radiation dose to achieve the same antitumor effect as mice harboring properly active immune system. [1]. Additionally, preclinical studies demonstrated reduced RT efficacy in natural killer cells (NK) or macrophages or dendritic cells (DC) – deficient animals [2]. Furthermore, interferon gamma (IFN-γ) was documented to serve as the main factor in CD8+T cells activation, as key effectors in response to RT [3, 4].

Cancer cells accumulate genetic alterations and loss of normal regulatory processes. This results in expression of the neoantigens, differentiation antigens, and/or cancer nuclei antigens which may lead to presentation of the peptides through binding to major histocompatibility class I (MHC I) molecules on the surface of cancer cells [5, 6]. Such cancer-specific antigens may be recognized by CD8+ T cells produced spontaneously in cancer patients [7], and thus cancer cells may be distinguished from normal cells. Recent studies revealed that at the tumor bed, cancer cells rely on different normal cells and recruit accessory cells to support progression of the tumor [8]. Accessory cells include cells forming hematogenous and lymphatic vasculature, tissue stroma components (among them - tissue-specific mesenchymal support cells, soluble and insoluble matrices), as well as myeloid and lymphoid-lineage cells [5, 8]. Reciprocal interaction between cancer cells, accessory cells, their mediators, extracellular matrix components exists and is a dynamic process [5]. During an early phase of cancer development cancer cells are visible to immune system (through cancer-specific antigens and proinflammatory „danger" signals, and most of them are eliminated (cancer immunosurveillance). Further, the process is not so successful, and the tumor cells may enter the equilibrium phase, where they may be either maintained chronically or immunologically sculpted by immune „editors" to produce new populations of tumor variants [9]. Finally, during escape phase cancer cells are invisible to the immune system and this in clinically visible phase of cancer progression [9]. Elegant studies in mice

revealed that the continued deletion of cancer cells expressing T cell targets (immune editing) may enable cancer cells to avoid attack of the immune system [9]. There are multiple other factors contributing to the cancer cells escape from immunosurveillance: cancer cells variability (eg. proteasome dysfunction, loss of classic MHC I molecules, presence of ligand-1 for programmed cell death (PD-L1), immunosuppressive activity of tumor matrix, presence of cells promoting escape phase (eg. myeloid-derived stem cells, M2 macrophages, regulatory T cells – Treg, fibroblasts), soluble in tumor extracellular matrix suppressive factors (eg. adenosine, transforming growth factor -beta - TGF-β, vascular endothelial growth factor – VEGF) [5, 6].

Immune responses in tumor reflects a series of carefully regulated events [6]. Both the innate and adaptive immunity contributes to the immune system optimal activity. The difference between them is based on antigen specificity. Innate immunity, composed mainly from DC, myeloid cells/macrophages and NK, serves as early warning system and the gatekeeper to T cell activation [6]. The specialized receptors located on the innate immunity cells recognize potential danger targets, which should be eliminated by the host. Pathogen associated molecular pattern (PAMPs) or signals indicating tissue damage („danger") – danger-associated molecular patterns (DAMPs) are recognized by innate system, which leads to immune response [10]. Cells of the innate system play a role in an early phase of multistep inflammation process and facilitate full and robust immune adaptive response. The adaptive immunity consists primarily from B and T cells and provide different specificity of the immune system through B and T cell receptors activation [6, 11].

Radiation therapy and innate immunity

At the tumor burden, innate immunity allows for detection of signals indicating the presence of cell damage or danger (fig. 1) [12]. Radiation induces both cancer and normal cells leading to release of specific danger signals, that consequently activate multiple inflammatory pathways in innate immune cells. The danger signals include, among others, high-mobility group box protein-1 (HMGB1), calreticulin, complement, heat shock protein 70 (hsp70), cytosolic DNA, and adenosine triphosphate (ATP) [2]. These molecules are sensed by the innate immune cells, such as macrophages, DC via: toll-like receptor 4 (TLR-4), cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING), CD47 and NLR family pyrin domain containing protein 3 (NLRP3). These lead to release of mediators, such as cytokines and chemokines, which trigger an immune response [2].

Damaged cells release HMGB1protein, which binds to TLR-4 on the macrophages and DC. The innate immune cells are characterized by high levels of the receptor. The TLR-4 is the main receptor for bacterial lipopolysaccharide (LPS) as well. Similarly to LPS, HMGB1 stimulates innate immune cells to cytokines release and upregulation of different molecules, like MHC, CD80, CD86, which leads to T cells activation [2]. Following radiation, damage, cells express calreticulin on their surface, which is a phagocytic signal for macrophages and DC. The former cells engulf the dead cells and subsequently may present tumor antigens [13]. Recently, cytosolic DNA was indicated as critical inflammatory signal induced by radiation [12,14]. Direct and indirect, radiation damages of nuclear and mitochondrial DNA causes DNA fragments formation in the nucleus and in the cytosol. Cytosolic DNA fragments are recognized by intracellular protein called cyclic GAMP synthase (cGAS) that leads to cGAMP synthesis. It activates the endoplasmic reticulum-bound STING pathway leading to the activation of IFN-regulatory factor 3 (IRF3), and subsequent INF production [15, 16]. Innate immune cells, like macrophages and dendritic cells, are highly abundant in cGAS and STING,

which are required for optimal production of type I INF. Synthesis of type I INFs after RT is the prerequisite for inducing the anti-tumor cytosolic CD8+ T cell response, since it induces tumor associated antigens presentation on T cells [16–19]. Recent elegant study demonstrated that DNA exonuclease – 3'repair exonuclease 1 (Trex1) regulates RT-induced activation of cGAS-STING-IFN pathway through cleaving cytosolic DNA formed after radiation exposure [20]. It was revealed that sensitivity of radiation in part depends on Trex1 levels. Namely high levels of Trex1 prevent RT-induced INF production [20].

Radiation therapy and adaptive immunity

Cancer antigens are presented to T cells both at tumor burden or in draining lymph nodes mainly by extremally efficient DC. After antigen recognition and capture DC migrate to draining lymph nodes along with free tumor associated antigens (TAA). Soluble TAA are captured by DC localized at lymphatic tissue. At the lymphoid tissue DC present captured antigens, in the form of peptide-MHC I or MHC II molecule complexes, to naive (antigen inexperienced) T cells (first signal). Additional co-stimulation should proceed through CD80, CD70 and/or 4-1BB (second signal) as well trough cytokines eg. interleukin-12 (IL-12), type I IFN, IL-15 (third signal) (fig. 2). Naive CD8+ T cells differentiate into cytotoxic T lymphocytes (CTLs) exerting antitumor activity, whereas naive CD4+ cells differentiate into helper cells (T_H) or to Treg – Treg, which role is to decrease immune response [21, 22].

Immunologic synapse (adaptive response)

T cells migrate through blood and lymphatic vessels to the tumor microenvironment, where they face numerous barriers, like intrinsic regulators (eg. CD28 – CTLA-4 or PD-1 – PDL-1

systems – called check points regulators), extrinsic factors (Treg, Breg, myeloid cells), pro-tumor inflammatory microenvironment, tissue microenvironment-related DC inhibition, immune evasion of tumor target, tissue – specific alteration, like presence of fatty cells, desmofibrosis [23]. Killing of cancer cells via T cells release leads again to endogenous tumor associated antigens (TAA) release and further DC activation, closing so called „cancer-immunity cycle" [5, 6].

Radiation therapy causes the death of cancer cells due to DNA damage (eg. apoptosis, autophagy) during cell division or in interphase (eg lymphocytes) [24]. In this way it essentially contributes to exacerbation of the immune system response. Radiation leads to TAA and DAMPS release from cancer cells, deletion of anergic T cells and Treg, increase antigen processing, and increase the expression of death receptors, increase of the cytokine and chemokine production as well as stimulation of immune cells circulation through bloodstream [5]. On the other hand stereotactic radiation therapy (SRT)/ stereotactic body radiation therapy (SBRT) contributes to diminished number of lymphocytes within the tumor burden, myeloid-derived stem cells increase within the tumor and in the bloodstream, Treg increase, all of which leads to immunosuppression and resistance to immunotherapy [24].

In 1953 for the first time an „abscopal effect" of RT was described. Namely, after RT delivery to one site, the systemic response arises and nonirradiated tumors, being located far away from radiation fields diminish in size or disappeared [25]. From that time such cases were documented in the literature, particularly after hypofractionated regimens [26]. However, in real clinical practice this phenomenon is not frequently observed, probably due to existing, dominant immunologic tolerance mechanisms [24]. Many studies demonstrated that combining of RT and immunotherapy increases antitumor response [24, 27].

Combination of RT and immunotherapy

Currently two conception between an interplay of RT and immunotherapy exists:

- RT acts as vaccine, and increases/stimulates abscopal effect. This is an issue in cancer metastatic setting,
- RT contribution to immunologic modulation in case of radical treatment [26, 27].

It should be stressed that the maximal effect is seen when patients' immunological system is well-functioning. Thus frail patients are less likely to respond to RT combining with immunotherapy.

Influence of RT dose on immunologic response

Preclinical studies demonstrated that the best effect of combining of checkpoint inhibitors with RT is achieved when hypofractionation is used comparing to conventionally fractionated RT [28]. However, data from preclinical studies and early clinical experience are not uniform. Brooks et al [29] demonstrated that single fraction of 30 Gy resulted in higher CD8+ T cells infiltration and better tumor response than single 5 Gy fraction, single 20 Gy fraction or 10 x 3 Gy fractionation regimen.

In PEMBRO-RT phase III trial SBRT administration (3 x 8 Gy) to the non small-cell lung cancer (NSCLC) metastatic sites combined with pembrolizumab increased relative responses comparing to pembrolizumab alone (36 % *vs.* 18 %) [30]. Of note, the patients were irradiated to the lung tumors or lymph nodes metastases. On the other hand, Luke et al [31] demonstrated that SBRT administration to 2–4 metastatic sites (30–50 Gy/3–5 fractions) and

subsequent pembrolizumab therapy resulted only in 13% relative response rate. Interestingly, in the study increased expression of 4 preselected IFN-γ genes in postradiation biopsy samples significantly corelated with observed responses in non-irradiated metastatic lesions [31].

Experimental study implies that fractionated RT (8 Gy) induces better antitumor immune abscopal effect when comparing to single RT dose (20 Gy) [32]. Very elegant study, performed by Vanpouille-Box et al [20], demonstrated that after 3 x 8 Gy-fraction regimen double strand DNA fragments are present in the cell cytoplasm, whereas 20 Gy dose produces no such effect [20]. Doses above 12–18 Gy induces the activity of DNA exonuclease Trex1 in cancer cells and attenuates their immunogenicity by degrading DNA that accumulates in the cytosol upon RT [20]. Contrary, RT used at immunogenic doses (oscillating around 8 Gy per fraction) leads to accumulation of cytosolic double-stranded DNA (dsDNA) in cancer cells, which activates type I IFN (IFN-I) via the cGAS/STING pathway [20, 33]. The abscopal effect in mice is seen when high dose of RT (but not too high) is combined with anti-CTLA-4 and anti-PD-L1 treatment (tab. I) [20] .

Interestingly Menon et al. [34] demonstrated that addition of low-dose radiation (to tumors nonirradiated with high-dose) to SBRT combining with immunotherapy increases systemic response rates of metastatic disease. Furthermore, addition of very low radiation (2 x 1 Gy) to secondary tumors delivered with immunotherapy and high-dose RT to primary tumors (3 x 12 Gy), so called RadScopal technique, enhances systemic antitumor immune responses through overcoming the inhibitory tumor stroma [35].

Is it important what is irradiated?

Distinct results were obtained in different trials combining treatment with immunotherapy and SBRT delivered to the lymph nodes/lung tumors in PEMRO-RT trial resulted in doubling the response rate of combined treatment [30], whereas SBRT to different tumor sites included substantial number of bony sites (25% of irradiated lesions) did not result in high response rate [31]. Thus the type of irradiated site may by important to induce immunogenic cell death and a durable antitumor immunity.

MacGee et al [36] revealed that SBRT delivered to parenchymal sites (lung, liver) induces systemic immune changes, including a decrease in total number of NK and cytotoxic ($CD56^{dim}CD16^{+}$) NK cells, an increase in TIM-3+ NK cells, and an increase in activated memory CD4+ and CD8+ T cells. On the other hand, SBRT administered to non-parenchymal sites (bones, central nervous system) did not induce such changes. By comparing the immune response after RT to different organs, the data suggest that SBRT induces systemic immunologic changes dependently upon irradiated site. Based on the forementioned data, a question raises, if all or some metastatic sites should be irradiated to most efficiently increase the chance on immunogenic cell death and to achieve the best effect of combined RT and immunotherapy [29]. Brooks et al. [29] propose delivering SBRT to all or multiple lesions to enhance the probability of immunogenic cell death. Future trials directed to assess efficacy of SBRT/ immunotherapy should address the issue of number and localization of irradiated lesion as well as define biomarkers of the immunologic cell death [37].

The main effector cells of the immune system are lymphocytes. Radiation therapy volumes including large vessels, the heart, lymphatic structures (eg. lymph nodes, the spleen, bone marrow, thymus in children) may lead to transient or persistent lymphopenia [38]. Numerous clinical trials demonstrate that lymphopenia correlates with decreased

overall survival [39]. There is no data on radiation dose/lymphatic organ volume ratio to guide safety of RT to lymphatic sites, thus the as low as rationally allowed (ALARA) rule should be used. In so called „lymphocyte spraying RT", modern imaging methods and sophisticated RT techniques should be used to spare lymphatic organs and bone enriched with bone marrow as much as it is possible [38, 39]. Utilization of functional imaging, like positron emission tomography (PET) with different tracers, magnetic resonance imaging (MRI) or spectroscopy (SPECT) allow for identify active and inactive volumes of bone marrow, which may help for optimal RT planning to reduce active volume of the tissue in the radiation volume [39].

Another conception of improving the efficacy of SBRT/immunotherapy combination is based on the partial tumor irradiation. An example is the SBRT-PATHY trial, where SBRT (1–3 fractions, 10–12 Gy each) was delivered to exclusively hypoxic segment of bulky tumors [40]. Such treatment resulted in better SBRT outcomes by exploiting both bystander and abscopal effects [40]. Addition of immunotherapy to such RT might further improve survival. To date, no data exists on such combination efficacy.

Recently, ultrarapid ultrahigh dose rate FLASH RT was introduced. It delivers very high doses of radiation (8–20 Gy) in time less than 1 second(s) [26, 38]. FLASH produces changes in immunologic microenvironment in both tumor and normal tissues and allows for normal tissue sparing. Furthermore, spatially fractionated radiation therapy (SFRT), the intentionally use of heterogeneous doses of radiation to different subvolumes within the same tumor (high dose peaks separated by low dose areas) [26, 38]. Early studies revealed that FLASH induces release of TNF-α, which correlates with complete clinical response [26, 38]. The

introduction of the novel technologies in combination with immunotherapy is interesting, but requires further thorough studies.

Tumor immunoreactivity

Many studies revealed that the patients who most benefit from immunotherapy are those with cancers that have high mutational burden [41, 42]. These are for example skin melanomas or microsatellite-instability-high colorectal cancers. Sensitivity of such tumors results from formation of immunogenic, tumor-specific mutant neoantigens [41]. On the other hand some tumors do not respond to immunotherapy, like: estrogen receptor-positive breast cancer, prostate cancer. These tumors are characterized by limited mutational burden. Cancer cell clones with high mutational burden may be eliminated during progression of the disease as a result of cancer immunoediting, leading to outgrowth of tumor cell clones with reduced immunogenicity. It was documented that RT-induced neoantigens broaden immunotherapeutic window of cancers with low mutational loads [41]. As mentioned earlier, the cancer subtype matters in terms of immunoreactivity. Microsatellite-instability-high colorectal cancers are characterized by high mutational burden, contrary to other subtypes of colorectal cancers. Triple negative and HER positive breast cancers are enriched with lymphocyte infiltrations and are characterized by higher immunogenicity, contrary to estrogen receptor/progesterone receptor positive breast cancers [43].

Optimal timing and sequencing of SRT/SBRT and immunotherapy

Optimal sequence and timing of RT and immunotherapy combinations is the subject of numerous experimental and clinical studies [42, 44]. It should be taken into account that tumors are largely distinct in terms of primary site, histopathology, immunogenicity, and clinical stage. There are several therapeutic mechanisms exploited by immunotherapy. Currently, the most widely implemented is immune checkpoint blockade (ICB).

CTLA-4 blockade and RT

CTLA-4 inhibits an early stage T-cell development , thus contributes to maintaining immune tolerance. CTLA-4 inhibition prevent the downregulation of T-cell activity and reduce Treg activity [44]. Many experimental studies documented promising synergy between RT and anty-CTLA-4 inhibition in neoadjuvant, concurrent and adjuvant settings [44]. However, to date the optimal sequence is elusive. In experimental studies adding CTLA-4 inhibitors after RT produced increased tumor response and improved survival (in primary and metastatic situations) [44]. CTLA-4 inhibitor administration before RT followed by OX40 inhibitor produced better effects than giving them after RT [45].

In clinical settings ipilimumab administration within 4 weeks after SRT due to melanoma brain metastases resulted in higher response rate than giving the inhibitor after 4 weeks [46]. In retrospective study (46 patients) it was observed that ipilimumab administration before or during SRT (single fraction of 21 Gy) for brain metastases produced the best survival benefit and lowest rate of recurrence [47]. Closer to the last dose of ipilimumab delivery of SRS to brain metastases (within 5.5 months) corelated with the best intracranial control [48]. Baker et al. [49] demonstrated that in stage III–IV unresectable melanoma patients who received nonbrain RT, the longest median survival time was

achieved when ipilimumab was administered after RT as maintenance therapy comparing to induction delivery – before RT (39 *vs.* 9 months). Knisely et al. [50] reported similar outcomes in 77 melanoma brain metastatic patients after combining SRS and ipilimumab irrespective on the sequence of administration of the two modalities. In IMCISION (NCT03003637), a non-randomized phase Ib/IIa trial, 32 head and neck squamous cell carcinoma patients were treated with 2 doses (in weeks 1 and 3) of ICB using nivolumab (NIVO MONO, n = 6) or nivolumab plus a single dose of ipilimumab (COMBO, n = 26) prior to surgery [51]. Major pathological response was achieved in 35% of patients after COMBO ICB, whereas after NIVO MONO's – the rate was only 17 % [51].

In prospective trial, enrolling 24 locally advanced melanoma patients, ipilimumab was delivered at 3 mg/kg every 3 weeks for four doses in conjunction with RT (median dose was 40 Gy). In inoperable patients undergoing neoadjuvant/definitive combined treatment the objective response rate was 64%, with 4 of 10 evaluable patients achieving a radiographic complete response. Additional 3 patients in this cohort had a partial response and went on to surgical resection [52]. Furthermore, in the second cohort, where the high-risk of recurrence melanoma patients received the combined treatment postoperatively, as adjuvant therapy, the 6-, 12-, and 24-month relapse-free survival was 85 %, 69 %, and 62 %, respectively (with 2 years of follow-up) [52].

In prospective phase I trial conducted by Gynecology Oncology Cooperative Group enrolling 34 cervical cancer patients in clinical stage IB2 to IVA with positive pelvic lymph nodes (LNs), para-aortic LNs, or both, ipilimumab wad administered after definitive radiochemotherapy. Treatment was well tolerated and the 12-month overall survival (OS) was 90 %, and progression-free survival (PFS) was 81 % [53].

PD-1 blockade and RT

PD-1 present on the mature T lymphocytes inhibits the activation of T cells. It binds with PD-L1 and PD-L2 expressed on tumor cells and antigen-presenting cells. Nivolumab, pembrolizumab and cemiplimab are PD-1 inhibitors currently used in the clinic [42].

In murine breast model Verburgge et al. [54]. Observed that concurrently given PD-1 inhibition enhances RT efficacy. Furthermore, SBRT delivered 1 day before PD-1 blockade resulted in increased PD-1 blockade antitumor response [55].

A pooled analysis of the phase II PEMBRO-RT trial (NCT 02492568) and phase 1 and 2 MD Anderson Cancer Center (MDACC) trial (NCT02444741) performed in metastatic NSCLC [56]. Pembrolizumab was administered intravenously (200 mg every 3 weeks) with or without RT in both trials. In the PEMBRO-RT trial, the first dose of pembrolizumab was given sequentially less than 1 week after the last dose of SBRT (3 x 8 Gy), whereas in the MDACC trial, pembrolizumab was given concurrently with the first dose of RT (4 x 12.5 Gy or 15 x 3 Gy). Only unirradiated lesions were measured for response. Median PFS was 4.4 months with pembrolizumab alone versus 9.0 months with pembrolizumab plus RT (p = 0.045), and median OS was 8–7 months with pembrolizumab *versus* 19.2 months with pembrolizumab plus RT (p = 0·0004) [57]. In phase II NICOLAS trial enrolling 79 stage IIIA–B unresectable treatment-naive NSCLC patients, underwent standard, definitive radiochemotherapy plus nivolumab and subsequent nivolumab monotherapy as maintenance setting [58]. The 1-year PFS was 53.7% and the median PFS was 12.7 month. At an extended follow-up (median 32.6 months) median OS was 38.8 months and a 2-year OS rate was 63.7% [58] Secondary analysis of results from KEYNOTE-001 trial revealed that patients who had received RT before

pembrolizumab administration have longer PFS and OS than those undergoing

pembrolizumab therapy alone [59]. Multiple studies (mainly phase I and II) testing various

sequencing of RT and anti-PD-1 combinations have been published or are ongoing, among

others in: in head and neck, cervical, lung, gastrointestinal, genitourinary, breast cancer

patients as well as in central nervous system or hematologic malignancies [42]. Ongoing

phase III clinical trials are presented in table II.

PD-L1 blockade and RT

Increased PD-L1 expression on cancer cells allows tumors to evade the immune system. RT

increases the expression of PD-L1 in the tumor microenvironment and on CD8+ T-cells [42].

In experimental models concurrent administration of PD-L1 inhibitor and RT led to

improved survival comparing to sequential treatment [63]. A study in murine pancreatic

cancer model demonstrated that adding anti-PD-L1 antibody to high-dose RT significantly

improved tumor response and the delay of 7 days between RT and receipt of PD-L1 inhibition

abolished the radiosensitization effect [64]. Durvalumab, atezolizumab and avelumab are PD-

L1 inhibitors currently used in the clinic.

The efficacy of combining of durvalumab as maintenance therapy after concomitant

chemoradiation in clinical stage III NSCLC patients was demonstrated in elegant phase III

PACIFIC trial. Namely the 12-month PFS rate was 55.9% *versus* 35.3%, and the 18-month PFS

rate was 44.2% *versus* 27.0%. The response rate was higher with durvalumab than with

placebo (28.4% *vs*. 16.0%; p < 0.001), and the median duration of response was longer

(72.8% *vs*. 46.8% of the patients had an ongoing response at 18 months) [65]. Of note,

subgroup of patients who received durvalumab within 14 days after completion

radiochemotherapy had increased survival comparing to those, who were randomized after this period. Furthermore, durvalumab significantly prolonged OS, as compared with placebo (p = 0.0025) [66]. Estimated 5-year rates for durvalumab and placebo were 42.9% *versus* 33.4% for OS and 33.1% *versus* 19.0% for PFS [67]. Such spectacular results led to incorporating a new benchmark for standard of care in this setting.

Another, phase III randomized study (PACIFIC-4) examines the efficacy and safety of durvalumab with SBRT versus placebo with SBRT in patients with unresected clinical stage I/II lymph node-negative (T1 to T3N0M0) NSCLC [68]. An interesting randomized phase II study (NCT04786093) is ongoing, which is designed to determine the impact of SBRT and durvalumab on quality-of-life and oncologic outcomes in patients with advanced NSCLC. Durvalumab and SBRT, with each fraction of RT is given every other day on a standard stereotactic ablative RT schedule or every four weeks on the personalized ultra-fractionated stereotactic adaptive RT (PULSAR) schedule [69].

The randomized, phase III CALLA study to determine the efficacy and safety of durvalumab plus chemoradiotherapy versus chemoradiotherapy alone as treatment in locally advanced cervical cancer patients is active (NCT03830866) [70]. The results (PFS) are awaited.

Toxicity and tolerability of ICB and RT

In most cases RT and immunotherapy are characterized by distinct toxicity profile.

Meta-analysis of results obtained in 51 studies showed comparable grade 3–4 toxicity in using ICB plus RT compared to ICI alone in CNS melanoma metastases, NSCLC, and prostate cancer. Author concluded that ICIB plus RT is safe for future clinical trials in these cancers

[71]. Additionally, a pooled analysis of trials in the US Food and Drug Administration Database revealed that immune checkpoints inhibitors given within 90 days following RT did not appear to be associated with an increased risk of serious adverse effects [72].

RT combination with other forms of immunotherapy

Apart from immune checkpoints inhibitors, which are the most frequently applied during clinical practice, many other options of immunotherapy combined with RT are currently tested [44]. One of the options are combinations of RT with cancer vaccines, eg. dendritic cell vaccine (Sipuleucel-T), viral vaccines (rV-CEA/TRICOM or rV-PSA/rV-B7), or protein and peptide vaccines (Vitespene/Oncophage) [44]. Administration of RT with adoptive immunotherapy (T-cell therapy, CAR-T cell therapy, or NK cell therapy) is under early clinical investigation as well [jw]. Inclusion of cytokines (TGF-β, TNF-α, GM-SCF, IL-2, Il-7 and IL-15) to stimulate the innate and adaptive immune cells along with RT is also an interesting option, however cytokine toxic side effects may limit their usage in combination treatment with RT [44].

RT and steroids

Glucocorticosteroids are potent immune suppressants They trigger T cell apoptosis and may increase a number of Treg. Since the purpose of RT is to stimulate the immune system to act against tumor cells, steroids may prevent this function and abolish the production of new T cells and their priming and activation. In clinical studies with ipilimumab in melanoma patients undergoing SRS, steroids were given prophylactically to avoid brain edema [73–75].

Patients receiving steroids have had lower median survival rates that those who did not were given the regimen. However administering steroid during RT not interfere with the treatments results, since T cells may already be activated. This need to more precisely explained in dedicated studies. The optimal interval between steroid usage and beginning of immunotherapy should be also assessed

Currently it is recommended to avoid usage of steroid before administration of RT combined with immunotherapy. However, there is an indication to use steroids to mitigate side effect of immunotherapy [76].

Conclusions and future perspective

Despite encouraging results of many experimental and clinical studies on the combination of radiation therapy and different types of immunotherapy, there is a lack of uniform recommendation concerning the optimal composition of the two modalities in different clinical scenarios (primary or metastatic settings). There is a need to analyze the optimal combinations of RT and immunotherapy in terms of their influence on particular tumor, tumor microenvironment and immune response. Influence of histopathology, biological characteristics of the tumor, its localization, primary or metastatic site irradiation, RT delivery to one or multiple sites, to the only one or all sites, type of site undergoing irradiation (eg. bone or lung tissue), optimal sequence of the combined therapy, the duration of immunotherapy, total and fractional radiation dose, etc. should be widely studied. There is a need to find predictive factors (eg. total mutation burden, total lymphocyte count, p53 status, calreticulin expression, Trex1 level or activity of STING) allowing for best choice of proper treatment options for the individual patient.

Conflict of interest: none declared

Ewa Sierko

Bialystok Oncology Centre

Radiotherapy Department 1

ul. Ogrodowa 12

15-027 Białystok, Poland

e-mail: esierko@onkologia.bialystok.pl

References

1. Stone HB, Peters LJ, Milas L. Effect of host immune capability on radiocurability and subsequent translatability of a murine fibrosarcoma. J Natl Cancer Inst 1979; 63: 1229-35

2. Dar TB, Henson RM, Shiao SL. Targeting innate immunity to enhance the efficacy of radiation therapy. Front Immunol 2019; 9: 3077. doi: 10.3389/fimmu.2018.03077

3. Lugade AA, Sorensen EW, Gerber SA et al. Radiation-induced IFN gamma production within the tumor microenvironment influences antitumor immunity. J Immunol 2008; 180: 3132-9 . doi: 10.4049/jimmunol.180.5.3132

4. Shiao SL, Ruffell B, DeNardo DG et al. TH2-polarized CD4(+) T cells and macrophages limit efficacy of radiotherapy. Cancer Immunol Res 2015: 3: 518-25. doi: 10.1158/2326-6066.CIR-14-0232

5. Palucka AK, Coussens LM. The basis of oncoimmunology. Cell 2016; 164: 1233-47. doi: 10.1016/j.cell.2016.01.049

6. Chen DS., Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39: 1-10. doi: 10.1016/j.immuni.2013.07.012

7. Boon T, Cerottini JC, van den Eynde B et al. Tumor antigens recognized by T lyphocytes. Annu Rev Immunol 1944; 12: 337-65. doi: 10.1146/annurev.iy.12.040194.002005

8. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor environment. Cancer Cell 2012; 21: 309-22. doi: 10.1016/j.ccr.2012.02.022

9. Dunn GP, Lloyd JO, Schreiber RD. The immunology of cancer immunosurveillance and immunoediting. Immunity 2004; 137: 137-48. doi: 10.1016/j.immuni.2004.07.017

10. Garg AD, Agostinis P. Cell death and immunity in cancer: from danger signals to mimicry of pathogen defense responses. Immunol Rev 2017; 280: 126-48. doi: [10.1111/imr.12574](10.1111/imr.12574)

11. Yang M, McKay D, Pollard JW et al. Divers functions of macrophages in different tumor microenvironments. Cancer Res 2018; 78: 5492-503. doi: 10.1158/0008-5472.CAN-18-1367

12. Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon dependent antitumor immunity in immunogenic tumors. Immunity 2014; 41: 843–52. doi: 10.1016/j.immuni.2014.10.019 33.

13. Chao MP, Weissman-Tsukamoto R, Alizadeh AA et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med. 2010; 2: 63ra94. doi:10.1126/scitranslmed.3001375

14. Deng L, Liang H, Fu S, Weichselbaum RR, Fu YX. From DNA damage to nucleic acid sensing: a strategy to enhance radiation therapy. Clin Cancer Res. 2016; 22: 20–5. doi: 10.1158/1078-0432.CCR-14-3110 34

15. Chen Q, Sun L, Chen ZJ. Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat Immunol. 2016; 17: 1142–9. doi: 10.1038/ni.3558 35.

16. Woo SR, Fuertes MB, Corrales L et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014; 41: 830–42. doi: 10.1016/j.immuni.2014.10.017

17. Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signaling. Nature 2008; 455: 674–8. doi: 10.1038/nature07317 38.

18. Ishikawa H, Ma Z, Barber GN. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 2009; 461: 788–92. doi: 10.1038/nature08476 39.

19. Li T, Chen ZJ. The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer. J Exp Med. 2018; 215: 1287–99. doi: 10.1084/jem.20180139

20. Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, et al. DNA exonuclease Trex1 regulates radiotherapy induced tumour immunogenicity. Nat Commun. 2017; 8: 15618. doi: 10.1038/ncomms15618

21. Brandmaier A, Formenti S. The impact of radiation therapy on innate and adaptive immunity. Sem Radiat Oncol 2019; 30: 139-144. doi: org/10.1016/j.semtadonc.2019.12.005

22. Appay V, Douek DC, Price DA. CD8+ T cell efficacy in vaccination and disease. Nat Med 2008; 14: 623-8. doi: 10.1038/nm.f.1774.

23. Ostrand-Rosenberg S, Horn LA, Ciavattone NG. Radiotherapy both promotes and inhibits myeloid-derived suppressor cell function: novel strategies for preventing the tumor-protective effects of radiotherapy. Front Oncol 2019: 9: 215. Doi: 10.3389/front.2019.00215

24. Liu Y, Dong Y, Kong l et al. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol Oncol 2018; 11: 104. doi: 10.1186/s13045-018-0647-8

25. Demaria S, Formenti sc. The abscopal effect 67 years later: from a side story to center stage. Br J Radiol. 2020; 93: 20200042. doi: 10.1259/bjr.20200042

26. Dutt S, Ahmed MM, Loo Jr BW et al. Novel Radiation Therapy Paradigms and Immunomodulation: Heresies and Hope. Semin Radiat Oncol 2020; 30: 194-200. doi: 10.1016/j.semradonc.2019.12.006.

27. Arina A, Gutiontov SL, Weichselbaum. Radiotherapy and immunotherapy for cancer: from "systemic" to "multisite". Clin Cancer Res 2020; 26: 2777-82. doi: 10.1158/1078-0432.CCR-19-2032

28. Lan J, Li R, Yin LM, Deng L et al. Targeting myeloid-derived suppressor cells and programmed death ligand 1 confers therapeutic advantage of ablative hypofractionated radiation therapy compared with conventional fractionated radiation therapy. Int J Radiat Oncol Biol Phys. 2018; 101: 74-87. doi: 10.1016/j.ijrobp.2018.01.071.

29. Brooks ED, Chang JY. Time to abandon single-site irradiation for inducing abscopal effects. Nat Rev Clin Oncol 2019; 31: 123-35. doi: 10.1038/s41571-018-0119-7

30. Theelen WSME, Peulen HMU, Lalezari F et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced Non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol. 2019; 5: 1276-82. doi: 10.1001/jamaoncol.2019.1478.

31. Luke JJ, Lemons JM, Karrison TG et al. Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors. J Clin Oncol 2018; 36(: 1611-1618. doi: 10.1200/JCO.2017.76.2229.

32. Dewan M Z, Galloway A, Kawashima N et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009; 15: 5379-88. doi: 10.1158/1078-0432.CCR-09-0265.

33. Diamond JM, Vanpouille-Box C, Spada S et al. Exosomes shuttle TREX1-sensitive IFN-stimulatory dsDNA from irradiated cancer cells to DCs. Cancer Immunol Res 2018; 6: 910-20. doi: 10.1158/2326-6066.CIR-17-0581.

34. Menon H, Chen D, Ramariyan R et al. Influence of low-dose radiation on abscopal

responses in patients receiving high-dose radiation and immunotherapy. J

Immunother Cancer 2019; 7: 237. doi: 10.1186/s40425-019-0718-6.

35. Barsoumian HB, Ramapriyan R, Younes AI et al. Low-dose radiation treatment

enhances systemic antitumor immune responses by overcoming the inhibitory

stroma. J Immunother Cancer 2020; 8: e000537. doi: 10.1136/jitc-2020-000537

36. McGee HE, Daly HE, Azghadi S et al. Stereotactic ablative radiation therapy induces

systemic differences in peripheral blood immunophenotype dependent on irradiated

site. Int J Radiat Oncol Biol Phys 2018; 101: 1259-70. doi:

10.1016/j.ijrobp.2018.04.038.

37. Kasmann L, Eze C, Manapov F. Stereotactic body radiation therapy (SBRT) combined

with immune check-point inhibition (ICI) in advanced lung cancer: which metastatic

site should be irradiated to induce immunogenic cell death? Int J Radiat Oncol Biol

Phys 2020; 108: 225-6. doi: 10.1016/j.ijrobp.2020.04.002

38. Lambin P, Lieverse RIY, Eckert F et al. Lymphocyte-sparing radiotherapy: the rationale

for protecting lymphocyte-rich organs when combining radiotherapy with

immunotherapy. Semin Radiat Oncol 2019: 30: 187-93. doi:

org/10.1016/j.semradonc.2019.12.003

39. Kuncman Ł, Pietrzykowska-Kuncman M, Danielska J et al. Nowotwory J Oncol 2017;

67: 301-7, doi: 10.5603/NJO.2017.0050

40. Tubin S, Popper HH, Brcic L et al. Novel stereotactic body radiation therapy (SBRT)-

based partial tumor irradiation targeting hypoxic segment of bulky tumors (SBRT-

PATHY): improvement of the radiotherapy outcome by exploiting the bystander and

abscopal effects. Radiat Oncol 2019; 14: 21. doi: 10.1186/s13014-019-1227-y.

41. Lussier DM, Alspach E, Warf JP et al. Radiation-induced neoantigens broaden the

immunotherapeutic window of cancers with low mutational loads. PNAS 2021; 118:

e2102611118. doi: 10.1073/pnas.2102611118.

42. Williamson CW, Sherer MV, Zamarin D et al. Immunotherapy and radiation therapy sequencing: state of the data on timing, efficacy, and safety. Cancer 2021; 127: 1553-67. doi: 10.1002/cncr.33424

43. Ho AY, Wright JL, Blitzblau RC et al. Optimizing radiation therapy to boost systemic immune responses in breast cancer: a critical review for breast radiation oncologists. Int J Radiat Oncol Biol Phys 2020; 108: 227-241. doi:10.1016/j.ijrobp.2020.05.011.

44. Aliru M, Schoenhals JE, Venkatesulu BP et al. Radiation therapy and immunotherapy: what is the optimal timing and sequencing? Immunotherapy 2018; 10: 299-316. doi: 10.2217/imt-2017-0082

45. Young KH, Baird JR, Savage et al. Optimizing timing of immunotherapy improves control of tumors by hypofractionated radiation therapy. PLoS One 2016: 11: e0157164. doi: 10.1371/journal.pone.0157164

46. Qian JM, Yu JB, Kluger HM et al. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer 2016: 122: 3051-8. doi: 10.1002/cncr.30138

47. Kiess AP, Wolchok JD, Barker CA et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 2015; 92: 368-75. doi: 10.1016/j.ijrobp.2015.01.004

48. Jiang W, Rodriguez Y, Kim B et al. Temporally-dependent intracranial control of melanoma brain metastasis by stereotactic radiation therapy in patients treated with immune checkpoint blockade. Int J Radiat Oncol Biol Phys 2015: 93: S57

49. Baker CA, Postow MA, Khan SA et al. Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res 2013: 1: 92-8. doi: 10.1158/2326-6066.CIR-13-0082

50. Knisely JPS, Yu JB, Flanigan J et al. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 2012; 117: 227-33. doi: 10.3171/2012.5.JNS111929

51. Vos JL, Elbers JBW, Krijgsman O. Neoadjuvant immunotherapy with nivolumab and

    ipilimumab induces major pathological responses in patients with head and neck

    squamous cell carcinoma. Nat Commun 2021;12: 7348. doi: 10.1038/s41467-021-

    26472-9.
52. Salama AKS, Palta M, Rushing CN. Ipilimumab and radiation in patients with high-risk

    resected or regionally advanced melanoma. Clin Cancer Res 202; 27:1287-1295. doi:

    10.1158/1078-0432.CCR-20-2452.
53. Mayadev JS, Enserro S, Lin YG et al. Sequential ipilimumab after chemoradiotherapy

    in curative-intent treatment of patients with node-positive cervical cancer. JAMA

    Oncol 2020; 6: 92-99. doi: 10.1001/jamaoncol.2019.3857.
54. Verbrugge I, Hagekyriakou J, Sharp LL et al. Radiotherapy increases the

    permissiveness of established mammary tumors to rejection by immunomodulatory

    antibodies. Cancer Res 2012; 72: 3163-74. doi: 10.1158/0008-5472.CAN-12-0210
55. Sharabi AB, Nirschl CJ, Kochel CM et al. Stereotactic radiation therapy augments

    antigen -specific PD-1-mediated antitumor immune responses via cross-presentation

    of tumor antigen. Cancer Immunol Res 2015; 3: 345-55. doi: 10.1158/2326-6066.CIR-

    14-0196
56. Theelen WSME, Peulen HMU, Lalezari F et al. Effect of pembrolizumab after

    stereotactic body radiotherapy vs pembrolizumab alone on tumor response in

    patients with advanced Non-small cell lung cancer: results of the PEMBRO-RT phase 2

    randomized clinical trial. JAMA Oncol. 2019; 5: 1276-1282. doi:

    10.1001/jamaoncol.2019.1478.
57. Theelen WSME, Chen D, Verma Vet al. Pembrolizumab with or without radiotherapy

    for metastatic non-small-cell lung cancer: a pooled analysis of two randomized trials.

    Lancet Respir Med. 2021; 9: 467-475. doi: 10.1016/S2213-2600(20)30391-X.
58. Peters S, Felip E, Dafni U et al. Progression-free and overall survival for concurrent

    nivolumab with standard concurrent chemoradiotherapy in locally advanced stage

IIIA-B NSCLC: results from the European Thoracic Oncology Platform NICOLAS phase II trial (European Thoracic Oncology Platform 6-14). J Thorac Oncol 2021; 16:278-288. doi: 10.1016/j.jtho.2020.10.129.

59. Shaverdian N, Lisberg AE, Bornazyan K et al. Previous radiotherapy and the clinical activity and toxicity of pemrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 2017; 18: 895-903. doi: 10.1016/S1470-2045(17)30380-7

60. https://clinicaltrials.gov/ct2/results?cond=&term=NCT03700905&cntry=&state=&city=&dist=

61. https://clinicaltrials.gov/ct2/results?cond=&term=NCT04365036&cntry=&state=&city=&dist=

62. https://clinicaltrials.gov/ct2/results?cond=&term=NCT+04221945&cntry=&state=&city=&dist=

63. Dovedi SJ, Adlard A, Lipowska-Bhalla G et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 2014; 74: 5458-68. doi: 10.1158/0008-5472.CAN-14-1258.

64. Azad A, Yin Lim S, D'Costa Z et al.PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. EMBO Mol Med 2017; 9: 167-80. doi: 10.15252/emmm.201606674

65. Antonia SJ, Villegas A, Daniel D et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017; 377: 1919-1929. doi: 10.1056/NEJMoa1709937.

66. Antonia SJ, Villegas A, Daniel D et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018; 379: 2342-2350. doi: 10.1056/NEJMoa1809697.

67. Spigel DR, Faivre-Finn C, Gray JE et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 2022; 40: 1301-1311. doi: 10.1200/JCO.21.01308.

68. https://clinicaltrials.gov/ct2/show/NCT04786093?

    term=durvalumab+radiation+therapy&draw=2&rank=6
69. https://clinicaltrials.gov/ct2/show/NCT03830866?

    term=NCT+03830866&draw=2&rank=1
70. https://clinicaltrials.gov/ct2/show/NCT04786093?

    term=NCT04786093&draw=2&rank=1
71. Sha CM, Lehrer EJ, Hwang C et al. Toxicity in combination immune checkpoint

    inhibitor and radiation therapy: a systematic review and meta-analysis. Radiother

    Oncol. 2020 Oct;151:141-148. doi: 10.1016/j.radonc.2020.07.035.
72. Anscher MS, Arora S, Weinstock C et al. Association of radiation therapy with risk of

    adverse events in patients receiving immunotherapy: a pooled analysis of trials in the

    US Food and Drug Administration Database. JAMA Oncol 2022; 8:232-240. doi:

    10.1001/jamaoncol.2021.6439.
73. Schoenfeld JD, Mahadevan A, Floyd SR et al. Ipilimumab and cranial radiation in

    metastatic melanoma patients: a case series and review. J Immunother Cancer 2015:

    3: 50. doi: 10.1186/s40425-015-0095-8
74. Weber J, Thomson JA, Hamid O et al. A randomized, double-blind, placebo-controlled,

    phase II study comparing the tolerability and efficacy of ipilimumab administered

    with or without prophylactic budesonide in patients with unresectable stage III or IV

    melanoma. Clin Cancer Res 2009; 15: 5591-8. doi: 10.1158/1078-0432.CCR-09-1024
75. Mathew M, Tam M, Ott PA et al. Ipilimumab in melanoma with limited brain

    metastases treated with stereotactic radiosurgery. Melanoma Res 2013; 23: 191-5.

    doi: 10.1097/CMR.0b013e32835f3d90
76. Bourke JM, O'Sullivan M, Khattak MA. Management of adverse events related to new

    cancer immunotherapy (immune checkpoint inhibitors). Med J Aust 2016: 205: 418-

   24. doi: 10.5694/mja16.00586

Figure 1. Innate immunity and radiation therapy

HMGB1 – high-mobility group box protein-1, ATP and adenosine triphosphate; CRT – calreticulin; Hsp70 – heat shock

protein 70; IFN – interferon; IL-1β – interleukin 1β; TNF-α – tumor necrosis factor-α; RT- radiation therapy

Figure 2. Immunologic synapse (adaptive response)

Table I. Influence of radiation does on immune response

	Radiation dose per fraction (Gy)		
	≤2	4–10	>10
tumor cells	• cancer cell apoptosis • not effective in boosting TAA and DAMPs generation	• cancer cell death • no immunosupression	• cancer cell necrosis • tissue damage • increased cancer cel killing • increased TAA and DAMPs release
immune response	• no change in DCs phenotype and function • increased immunosuppresion • increased numer of MDSC, TGF-β, TAM M2 at the tumor burden • immune adiuvant effects • increased numer of CD8+ and CD4+ T cells • some TAMs repolarize toward M1 phenotype • lack of efficient antitumor response	• MHC-I up-regulation • DCs capture TAA • promotion of DCs migration tom the lymph nodes • MDSCs, Treg, M2-phenotypic traits decrease • macrophages increase • transient induction of proinlammatory microenvironment	• MHC-I up-rgulation and expression on DCs • inreased maturation of DCs, APCs • increased Type-I IFN production by DCs • increased number of CD45+ cells and CD8+ T cells • hipoxia-driven immunosuppresive microenvironment • increased number of MDSCs, tolerogenic TAMs M2, Tregs, TGF-β • triggering of innate and adaptive response

TAA – tumor associated antigen; DAMPs – damage and molecular patterns; DCs – dendritic cellc; MDSCs – myeloid-derived stem cells; TGF-β – transforming growth factor beta; TAM M2 or -M1 – tumor associated macrophages-M2 or -M1; MHC-I – mail histocompatibility complex-I; Treg – regulatory T cell; APCs – antigen presenting cells; Type-I IFN – interferon type-I; Gy – grey

Table 2. Phase III pending trials involving PD-1 inhibition and radiation therapy

Clinicaltrials.gov identifier [reference]	Setting	Treatment	Endpoint
NCT03700905 [60]	postoperative head and neck cancer	nivolumab or nivolumab plus ipilimumab after	DSF

		surgical resection and adjuvant RT or RT-CT	
NCT04365036 [61]	early stage natural killer/T-cell lymphoma	toripalimab and induction CT followed by RT with concurrent toripalimab vs induction CT followed by RT	PFS
NCT 04221945 [62]	locally advanced cervical cancer	CH-RT with or without concurrent pembrolizumab	PFS, OS

RT – radiation therapy; CT – chemotherapy; RT-CT – concurrent radiochemotherapy; DFS – disease free survival; PFS – progression free survival; OS – overall survival